Browsing: Basic > Drug Development
In this interview we speak to Keith Kaye, from the University of Michigan (MI, USA) about the RESTORE-IMI 2 study, its results and why ICU patients represent an unmet need.
Bacteriophage have been touted as the solution for antibiotic resistant microbes, why are they not being used in mainstream medicine?
Take a look at this month’s industry headlines including US FDA approvals for XOFLUZATM and a rapid diagnostic test for…
Researchers have developed nanomeshes as an effective drug-delivery system for antibiotics.
Take a look behind the scenes of a recent Future Microbiology review, entitled ‘Anti-Candida activity of existing antibiotics and their derivatives when used alone or in combination with antifungals’ as we ask the authors about Candida infections, the potential repurposing of antibiotics and the future of this field.
A team from the Broad Institute at MIT and Harvard have designed a Cas13–CRISPR construct, termed CARVER, that can detect and kill viruses inside human cells. The flexible CARVER system could be used as a new tool in research and the clinic.
In this interview we speak to Pinaki Panigrahi about his work using probiotics as a preventative strategy against sepsis in neonates. In addition, he comments on the impact of probiotics for other infections and some of the skepticism surrounding some microbiome research.
Take a look at this month’s industry headlines including FDA warnings over hepatitis C drugs in patients with liver injury, a new infectious diseases strategy for the UK and priority review for Merck’s Ebola vaccine.
In this interview, Paul Rowley (University of Idaho, ID, USA) speaks about his research identifying novel antifungal proteins from Saccharomyces cerevisiae yeasts and whether these could be translated into the medications of the future.